Assessment of drug use and quality of life in patients with type 2 diabetes using vildagliptin and speckle tracking changed

Introduction: It is of key importance to assess medication use in type 2 diabetes mellitus patients. Quality of life should also be investigated, as it may be affected by the required therapeutic strategies. Objective: Assessing medication use and quality of life in type 2 diabetes mellitus patients using vildagliptin. Materials and methods: It is a longitudinal, prospective and intervention study. Sociodemographic, clinical, and other three tools were collected. Two for quality-of-life assessment and one for medication use assessment. The 32 patients were followed for seven months and received vildagliptin. Speckle tracking echocardiography, laboratory tests, follow-up with cardiologist, endocrinologist and weekly empowerment workshops with a multidisciplinary team were performed, as well as telephone contact. Results: When comparing B-PAID and WHOQOL-bref scores before and after the intervention, p-value was <0.001 in all domains. Regarding speckle tracking, there was improvement, and the mean speckle tracking of patients was -15.4% and -17.6%. Patients’ mean glycated hemoglobin was 9.5% and at the end of the intervention was 6.9%. Regarding medication use, at the end of the intervention, patients were engaged. It was also observed improvement of hemodynamic parameters and physical fitness, with proportional increase of the metabolic equivalent value. Conclusions: The empowerment program associated with treatment optimization and medication use improved the metabolic control of type 2 diabetes mellitus in users of this study.